Literature DB >> 15141012

Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.

Mustafa K Ozvaran1, Xiaobo X Cao, Steven D Miller, Brett A Monia, Waun Ki Hong, W Roy Smythe.   

Abstract

OBJECTIVE: Malignant pleural mesothelioma (MPM) is resistant to both conventional chemotherapy and apoptosis. The bcl-2 family proteins are major determinants of apoptotic homeostasis. MPM lines and tumors routinely overexpress the anti-apoptotic protein BCL-XL. We have previously shown that antisense inhibition of BCL-XL in MPM cells leads to apoptosis. We sought to determine whether antisense oligonucleotides directed at the bcl-xl gene product would augment response to a conventional chemotherapeutic agent in human mesothelioma cell lines.
METHODS: The human MPM cell lines REN and I-45 were exposed to two bcl-xl antisense oligonucleotides (15999, 16009) and one sense oligonucleotide (113529) construct at varying doses, followed by IC(50) cisplatin. Cellular viability was assessed by a calorimetric assay, and apoptosis was evaluated by Hoechst staining, Annexin V staining, and sub-G(1) fluorescence-activated cell sorter analysis. Western blot analysis of BCL-2 family proteins was performed following single agent and combined treatment. Isobologram mathematical analysis was used to determine whether or not combination therapies were additive or synergistic.
RESULTS: Cell viability was most affected with the 15999 antisense oligonucleotides plus IC(50) cisplatin combination (70% of I-45 and 90% of REN cells killed), and apoptosis was markedly increased with this combination by all measures. Western blot demonstrated 15999 antisense oligonucleotides construct down-regulation of BCL-XL, but no further effect on expression of BCL-2 proteins with cisplatin. Isobologram analysis demonstrated 15999 + cisplatin synergistic effect.
CONCLUSIONS: Exposure of human MPM cells to bcl-xl antisense oligonucleotides sensitizes human mesothelioma cells to the conventional chemotherapeutic agent cisplatin. Similar approaches using a combination of molecular and conventional treatment may have clinical utility for this tumor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15141012

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  9 in total

1.  MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.

Authors:  Z Xie; C Bi; J Y Chooi; Z L Chan; N Mustafa; W J Chng
Journal:  Leukemia       Date:  2015-06-30       Impact factor: 11.528

2.  Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors.

Authors:  Xiaobo Cao; James Littlejohn; Charles Rodarte; Lidong Zhang; Benjamin Martino; Philip Rascoe; Kamran Hamid; Daniel Jupiter; W Roy Smythe
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

3.  MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.

Authors:  Zhigang Xie; Jing Yuan Chooi; Sabrina Hui Min Toh; Dongxiao Yang; Nurhidayah Binte Basri; Ying Swan Ho; Wee Joo Chng
Journal:  Leukemia       Date:  2018-11-23       Impact factor: 11.528

4.  Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.

Authors:  Zhigang Xie; Chonglei Bi; Lip Lee Cheong; Shaw Cheng Liu; Gaofeng Huang; Jianbiao Zhou; Qiang Yu; Chien-Shing Chen; Wee Joo Chng
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

5.  Cell-specific expression of artificial microRNAs targeting essential genes exhibit potent antitumor effect on hepatocellular carcinoma cells.

Authors:  Chenyu Mao; Hao Liu; Ping Chen; Jingjia Ye; Lisong Teng; Zhenyu Jia; Jiang Cao
Journal:  Oncotarget       Date:  2015-03-20

6.  BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.

Authors:  Surein Arulananda; Megan O'Brien; Marco Evangelista; Tiffany J Harris; Nikita S Steinohrt; Laura J Jenkins; Marzena Walkiewicz; Robert J J O'Donoghue; Ashleigh R Poh; Bibhusal Thapa; David S Williams; Trishe Leong; John M Mariadason; Xia Li; Jonathan Cebon; Erinna F Lee; Thomas John; W D Fairlie
Journal:  Cell Death Discov       Date:  2020-10-31

7.  Downregulation of miR-423-5p Contributes to the Radioresistance in Colorectal Cancer Cells.

Authors:  Yuanyuan Shang; Lingfei Wang; Zhe Zhu; Wei Gao; Dan Li; Zhuqing Zhou; Lin Chen; Chuan-Gang Fu
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

Review 8.  Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?

Authors:  S Baig; I Seevasant; J Mohamad; A Mukheem; H Z Huri; T Kamarul
Journal:  Cell Death Dis       Date:  2016-01-14       Impact factor: 8.469

Review 9.  Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.

Authors:  Bhairavi Tolani; Luis A Acevedo; Ngoc T Hoang; Biao He
Journal:  Int J Mol Sci       Date:  2018-01-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.